AJANTPHARM / Q3-FY24 / risks

Keep the risk register visible.

Ajanta Pharma · Material risks, their source context, and severity in the latest available quarter.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ3-FY24 · 2024-01-30Back to quarter ↗

Risk intelligence

Material risks this quarter

Red Sea crisis impacting freight costs and transit times

Freight costs may increase by ~0.5% of revenue (~INR 30-35 crore) and transit times by 15-20 days, potentially pressuring margins and working capital.

medium

US price erosion remains an unknown variable

While current price erosion is stable at high single digits, any acceleration could impact US generics profitability and overall margins.

high

Unpredictability of Africa institutional business

Institutional business is lumpy and dependent on agency funding and malaria season, making it difficult to forecast.

medium

NLEM price revisions impacting India cardiology growth

Cardiology growth was lower than IPM due to price revision in a major product in December 2022, and competitive intensity has increased.

medium